Breakthrough cord blood treatment shows promise for tough blood cancers
NCT ID NCT04103879
Summary
This study tested a new method to improve cord blood transplants for patients with high-risk leukemia or myelodysplasia who lack a perfect donor match. Researchers used a molecule called UM171 to expand the number of stem cells in cord blood before transplant, aiming to make the procedure safer and more effective. The study followed 30 patients to see if this approach could reduce complications and improve survival rates compared to standard cord blood transplants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORD BLOOD TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus Medical Center
Rotterdam, Gelderland, 3015, Netherlands
-
Fred Hutchinson / University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
University of Colorado School of Medicine. Anschutz Medical Campus
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.